EBOVAC2 is organised into 6 workpackages (WP), or groups of activities, in order to reach its objectives.

WP1 will oversee the activities of all work packages and interact with the overall EBOLA+ programme governance. WP2 will conduct the clinical trials, enroll volunteers, collect blood samples, and record clinical trial data. The collected blood samples will be sent to the laboratories participating in WP3 who will be in charge of the immunogenicity measurements of the trial samples. WP4 will be in close interaction with WP2 and WP3 to translate results from clinical to NHP research and vice versa. WP5 will manage the upload of EBOVAC2 data into the data repository. WP6 will be in charge of disseminating the information relative to the overall project (WP1) as well as milestones and results of each work package.

schema

WP1: Project coordination and management

The objectives of this WP are three-fold:

  • At the strategic level, to ensure that the project reaches its objectives and expected impacts;
  • At the managerial level, to put in place the procedures and tools needed to ensure that the project progresses in conformity with the work plan and produces timely and quality results as well as overseeing conformity of all activities to IMI JU rules and the Consortium agreement;

At the administrative level, to organise project meetings, prepare project reports, manage the project budget and payments.

Leader: Inserm

WP2: Clinical core

This WP aims to confirm the robustness of safety and immunogenicity of the Ad26.ZEBOV/MVA-BN-Filo heterologous prime boost vaccine regimen obtained in phase 1 trials through the conduct of phase 2 trials in European and African populations.

Leader: Inserm/Janssen

WP3: Immune monitoring (Phase II trial)

The objectives of this WP are to analyse the immunogenicity of the Ad26.ZEBOV/MVA-BN-Filo heterologous prime boost vaccine regimen in phase 2 trials conducted in European and African populations through:

  • Evaluation of the immune response to the prime/boost based on protocol-defined endpoints (core immuno assessment including T cell and antibody responses);
  • Extensive characterization of the immune response to the vaccine regimen (cellular functionality, neutralisation of living virus);
  • Description of the immune signature and to better understand the mechanism of the vaccine regimens effect through gene expression monitoring;

Integrative statistical analysis of the gene expression and functional assays to understand and predict the effect of the vaccine regimen on the immune system.

Leader: Inserm

WP4: Translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (NHP).

The objective of this WP is to carry out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates.

Leader: Inserm

WP5: Data management and integration

The primary objective of the data management and integration work package is to load EBOVAC2 data to the INFOCENTRE (joint Ebola+ program data collection platform) and conduct statistical analysis on the data available. This WP will be carried out in compliance with the consortium Information Governance Model and project agreement.

Leader: Janssen

WP6: Communication and Capacity Building

The objectives of this WP are to develop and implement a communication plan involving all relevant stakeholders and beneficiaries of EBOVAC2. In addition, best practices and procedures for performing clinical trials will be developed and medical and non-medical laboratory staff will be trained on prime boost vaccine management.

Leader: Inserm Transfert

Impact

  • Data to demonstrate the safety, immunogenicity and, potentially, the efficacy of the prime-boost vaccine regimen in prevent Ebola virus disease
  • Reduced disease burden: if proved effective the vaccine will also potentially contribute to preventing future epidemics, saving lives and reducing suffering and damage to health systems and wider society in affected countries
  • Capacity development in affected countries to ensure preparedness for future outbreaks

News

  • 12 September 2017

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 7-10 November, 2017 Registration - Enregistrement

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Nairobi, Kenya 28-30 November 2017. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research